Study reveals challenges and risks for women using anabolic-androgenic steroids

A new study published in Drug and Alcohol Review has revealed critical insights into the challenges and risks faced by women who use anabolic-androgenic steroids (AAS).

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

January 9, 2025

Lead drug from J&J and Addex’s 20-year collaboration flunks Phase 2 in epilepsy

The top experimental drug stemming from Johnson & Johnson’s long-running alliance with Addex Therapeutics has failed a Phase 2 epilepsy study, casting a shadow over

April 30, 2024

A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches.

February 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.